Updates are available Correction dated 2019-03-23

Article History

First Online: 23 January 2019

Change Date: 23 March 2019

Change Type: Correction

Change Details: The authors would like to note that several errors had occurred, especially in Table 2, Tables 5, 6 and 7, Figure 13, and in the legend of Figure 23.

Compliance with ethical standards

: All patients have provided informed consent for the off label use of statins and for permission to conduct experiments and publish the results. One case study with Graves’s orbitopathy has been published in poster format at the Endocrine Society Meeting 2018 in Chicago: Statins As Immunomodulatory Therapy In Graves’ Orbitopathy. Poster Presentation SAT-676, 100th Endocrine Society Meeting, Chicago, IL, March 17, 2018.

: Prof. Koch declares no direct conflict with this article. He has served on the Advisory Board of Novartis on the topic acromegaly and has participated in educational conferences on the topics neuroendocrine tumors and acromegaly sponsored by Novartis and Ipsen. Dr. Hehmke declares no conflict of interest. Prof. Krabbe declares no direct conflict with this article. He has served on the Advisory Board of Lilly and as speaker for Berlin-Chemie, Amgen, and MSD Sharp & Dohme / Merck & Co. Inc.Figure and Table legends are provided within the respective text sections.Reference [ ] and parts of the table from it are available as open access article and for reproduction use as long as the source is acknowledged / cited which is the case here.